Table 2.

Fine-Gray regression for major adverse cardiac events among all patients (N = 335).

Variable	Univariable		Multivariable
	sHR (95 % CI)	P	sHR (95 % CI)	P
Age (y)	1.04 (0.99–1.08)	0.089
Female	1.71 (0.86–3.44)	0.13
ECOG PS (ref: 0)
1	2.99 (1.14–7.81)	0.026	2.89 (1.03–7.87)1	0.042
2	6.11 (1.98–18.9)	0.0016	4.96 (1.57–15.6)1	0.0063
Smoking pack-years (per 10)	1.02 (0.93–1.10)	0.74
Baseline CVD	1.86 (0.94–3.69)	0.075
Baseline CHD	2.41 (1.22–4.77)	0.012	1.96 (0.98–3.92)1	0.056
Framingham risk (ref: low)2
Moderate	2.47 (0.29–21.3)	0.41
High	2.06 (0.26–16.6)	0.50
Baseline atrial fibrillation/flutter	0.72 (0.25–2.01)	0.52
Baseline hypertension	1.56 (0.73–3.33)	0.25
Baseline hyperlipidemia	1.12 (0.58–2.17)	0.73
Baseline diabetes	1.99 (0.99–4.00)	0.052
BMI (kg/m2)	1.03 (0.97–1.08)	0.36
Baseline statin use	2.06 (0.99–4.29)	0.052
Laterality of primary tumor (ref: right)
Left	0.54 (0.24–1.18)	0.12
Mediastinum	0.48 (0.066–3.55)	0.47
Proton therapy	1.24 (0.63–2.43)	0.53
Carboplatin/paclitaxel (ref: all else)	1.54 (0.69–3.43)	0.30
Consolidation ICI receipt	0.76 (0.38–1.50)	0.43
LAD V15Gy (%)3	0.99 (0.97–1.01)	0.37	0.99 (0.97–1.01)1	0.34
Heart mean dose (Gy)3	0.97 (0.92–1.02)	0.27	0.97 (0.92–1.03)4	0.30

sHR, subdistribution hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; ref, reference; CVD, cardiovascular disease; CHD, coronary heart disease; ICI, immune checkpoint inhibitor; LAD, left anterior descending coronary artery; Vx Gy, volume receiving ≥ x Gy.

¹Model 1 with ECOG PS, baseline CHD, and LAD V15Gy.

²Among the 196 patients without baseline CHD.

³Only LAD V15Gy and heart mean dose are included in this Table as they are representative dosimetric parameters; Supplementary Table 4 shows all univariable tests performed.

⁴Model 2 with ECOG PS, baseline CHD, and heart mean dose.